Value through Innovation27 July 2016

Clinical Study Results

  • BI 409306 - Alzheimer Disease
    Clinical Study Number 1289.7
    Study Indication Alzheimer Disease
    Product BI 409306
    Generic Name BI 409306
    Lab Code BI 409306
    Clinical Phase II
    Study Title

    A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy, safety and tolerability of orally administered BI 409306 during a 12-week treatment period compared to placebo in patients with cognitive impairment due to Alzheimer’s Disease

    Study Document Lay summary 1289.7 english
  • BI 409306 - Alzheimer Disease
    Clinical Study Number 1289.5
    Study Indication Alzheimer Disease
    Product BI 409306
    Generic Name BI 409306
    Lab Code BI 409306
    Clinical Phase II
    Study Title

    A multi-centre, double-blind, parallel-group, randomized controlled study to investigate the efficacy, safety and tolerability of orally administered BI 409306 during a 12-week treatment period compared to placebo in patients with Alzheimer’s Disease

    Study Document Lay summary 1289.5 english

Clinical Trial Registry and structured study results. Find here protocol information for all clinical study types.

European Trial Register of EU studies.